Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

South Korea Infrastructure Construction Market

ID: MRFR/CnM/46341-HCR
111 Pages
Snehal Singh
Last Updated: April 06, 2026

South Korea Infrastructure Construction Market Research Report: By Type (Energy Construction, Utilities Infrastructure Construction) andBy Application (Civil Use, Military Use)- Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

South Korea Infrastructure Construction Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Pharmaceutical, BY Type (USD Million)
  49.     4.1.1 Energy Construction
  50.     4.1.2 Utilities Infrastructure Construction
  51.   4.2 Pharmaceutical, BY Application (USD Million)
  52.     4.2.1 Civil Use
  53.     4.2.2 Military Use
  54. 5 SECTION V: COMPETITIVE ANALYSIS
  55.   5.1 Competitive Landscape
  56.     5.1.1 Overview
  57.     5.1.2 Competitive Analysis
  58.     5.1.3 Market share Analysis
  59.     5.1.4 Major Growth Strategy in the Pharmaceutical
  60.     5.1.5 Competitive Benchmarking
  61.     5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  62.     5.1.7 Key developments and growth strategies
  63.       5.1.7.1 New Product Launch/Service Deployment
  64.       5.1.7.2 Merger & Acquisitions
  65.       5.1.7.3 Joint Ventures
  66.     5.1.8 Major Players Financial Matrix
  67.       5.1.8.1 Sales and Operating Income
  68.       5.1.8.2 Major Players R&D Expenditure. 2023
  69.   5.2 Company Profiles
  70.     5.2.1 China Communications Construction Company (CN)
  71.       5.2.1.1 Financial Overview
  72.       5.2.1.2 Products Offered
  73.       5.2.1.3 Key Developments
  74.       5.2.1.4 SWOT Analysis
  75.       5.2.1.5 Key Strategies
  76.     5.2.2 Bechtel Corporation (US)
  77.       5.2.2.1 Financial Overview
  78.       5.2.2.2 Products Offered
  79.       5.2.2.3 Key Developments
  80.       5.2.2.4 SWOT Analysis
  81.       5.2.2.5 Key Strategies
  82.     5.2.3 Vinci SA (FR)
  83.       5.2.3.1 Financial Overview
  84.       5.2.3.2 Products Offered
  85.       5.2.3.3 Key Developments
  86.       5.2.3.4 SWOT Analysis
  87.       5.2.3.5 Key Strategies
  88.     5.2.4 Fluor Corporation (US)
  89.       5.2.4.1 Financial Overview
  90.       5.2.4.2 Products Offered
  91.       5.2.4.3 Key Developments
  92.       5.2.4.4 SWOT Analysis
  93.       5.2.4.5 Key Strategies
  94.     5.2.5 Skanska AB (SE)
  95.       5.2.5.1 Financial Overview
  96.       5.2.5.2 Products Offered
  97.       5.2.5.3 Key Developments
  98.       5.2.5.4 SWOT Analysis
  99.       5.2.5.5 Key Strategies
  100.     5.2.6 ACS Group (ES)
  101.       5.2.6.1 Financial Overview
  102.       5.2.6.2 Products Offered
  103.       5.2.6.3 Key Developments
  104.       5.2.6.4 SWOT Analysis
  105.       5.2.6.5 Key Strategies
  106.     5.2.7 Kiewit Corporation (US)
  107.       5.2.7.1 Financial Overview
  108.       5.2.7.2 Products Offered
  109.       5.2.7.3 Key Developments
  110.       5.2.7.4 SWOT Analysis
  111.       5.2.7.5 Key Strategies
  112.     5.2.8 Balfour Beatty plc (GB)
  113.       5.2.8.1 Financial Overview
  114.       5.2.8.2 Products Offered
  115.       5.2.8.3 Key Developments
  116.       5.2.8.4 SWOT Analysis
  117.       5.2.8.5 Key Strategies
  118.     5.2.9 Strabag SE (AT)
  119.       5.2.9.1 Financial Overview
  120.       5.2.9.2 Products Offered
  121.       5.2.9.3 Key Developments
  122.       5.2.9.4 SWOT Analysis
  123.       5.2.9.5 Key Strategies
  124.   5.3 Appendix
  125.     5.3.1 References
  126.     5.3.2 Related Reports
  127. 6 LIST OF FIGURES
  128.   6.1 MARKET SYNOPSIS
  129.   6.2 SOUTH KOREA MARKET ANALYSIS BY TYPE
  130.   6.3 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
  131.   6.4 KEY BUYING CRITERIA OF PHARMACEUTICAL
  132.   6.5 RESEARCH PROCESS OF MRFR
  133.   6.6 DRO ANALYSIS OF PHARMACEUTICAL
  134.   6.7 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
  135.   6.8 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
  136.   6.9 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
  137.   6.10 PHARMACEUTICAL, BY TYPE, 2024 (% SHARE)
  138.   6.11 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (USD Million)
  139.   6.12 PHARMACEUTICAL, BY TYPE, 2024 TO 2035 (Kilo Tons)
  140.   6.13 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
  141.   6.14 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
  142.   6.15 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (Kilo Tons)
  143.   6.16 BENCHMARKING OF MAJOR COMPETITORS
  144. 7 LIST OF TABLES
  145.   7.1 LIST OF ASSUMPTIONS
  146.     7.1.1
  147.   7.2 South Korea MARKET SIZE ESTIMATES; FORECAST
  148.     7.2.1 BY TYPE, 2025-2035 (USD Million)
  149.     7.2.2 BY TYPE, 2025-2035 (Kilo Tons)
  150.     7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  151.     7.2.4 BY APPLICATION, 2025-2035 (Kilo Tons)
  152.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  153.     7.3.1
  154.   7.4 ACQUISITION/PARTNERSHIP
  155.     7.4.1

South Korea Pharmaceutical Market Segmentation

Pharmaceutical By Type (USD Million, 2025-2035)

  • Energy Construction
  • Utilities Infrastructure Construction

Pharmaceutical By Application (USD Million, 2025-2035)

  • Civil Use
  • Military Use

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions